{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:52:51Z","timestamp":1771555971640,"version":"3.50.1"},"reference-count":49,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Multiple myeloma (MM) is a B-cell malignancy that is incurable for a majority of patients. B-cell maturation antigen (BCMA) is a lineage-restricted differentiation protein highly expressed in multiple myeloma cells but not in other normal tissues except normal plasma B cells. Due to the restricted expression and being a cell surface membrane protein, BCMA is an ideal target for immunotherapy approaches in MM. Recombinant immunotoxins (RITs) are a novel class of protein therapeutics that are composed of the Fv or Fab portion of an antibody fused to a cytotoxic agent. RITs were produced by expressing plasmids encoding the components of the anti-BCMA RITs in E. coli followed by inclusion body preparation, solubilization, renaturation, and purification by column chromatography. The cytotoxic activity of RITs was tested in vitro by WST-8 assays using BCMA expressing cell lines and on cells isolated from MM patients. The in vivo efficacy of RITs was tested in a xenograft mouse model using BCMA expressing multiple myeloma cell lines. Anti-BCMA recombinant immunotoxins are very effective in killing myeloma cell lines and cells isolated from myeloma patients expressing BCMA. Two mouse models of myeloma showed that the anti-BCMA immunotoxins can produce a long-term complete response and warrant further preclinical development.<\/jats:p>","DOI":"10.3390\/biom10101387","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T08:43:27Z","timestamp":1601369007000},"page":"1387","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8779-4004","authenticated-orcid":false,"given":"Tapan K.","family":"Bera","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_2","unstructured":"(2020, June 26). Key Statistics About Multiple Myeloma. Available online: https:\/\/www.cancer.org\/cancer\/multiple-myeloma\/about\/key-statistics.htmls."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1073\/pnas.77.3.1588","article-title":"Discrete stages of human intrathymic differentiation: Analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage","volume":"77","author":"Reinherz","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1002\/j.1460-2075.1992.tb05482.x","article-title":"A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma","volume":"11","author":"Gras","year":"1992","journal-title":"EMBO J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1128\/MCB.21.12.4067-4074.2001","article-title":"B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses","volume":"21","author":"Xu","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"Raman","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_10","first-page":"E174","article-title":"Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment","volume":"19","author":"Jew","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1158\/1535-7163.MCT-07-0464","article-title":"Antibody targeting of B-cell maturation antigen on malignant plasma cells","volume":"6","author":"Ryan","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1021\/jacs.5b01876","article-title":"An anti-B cell maturation antigen bispecific antibody for multiple myeloma","volume":"137","author":"Ramadoss","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/ijc.33002","article-title":"B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives","volume":"147","author":"Sellner","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/14737140.2019.1586539","article-title":"Anti-BCMA antibodies in the future management of multiple myeloma","volume":"19","author":"Gavriatopoulou","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2217\/imt-2018-0199","article-title":"B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma","volume":"11","author":"Eckhert","year":"2019","journal-title":"Immunotherapy"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): A dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Costa, L.J., Quach, H., Stockerl-Goldstei, K., Augustson, B., Ferron-Brady, G., Chopra, B., Moore, A., Hudson, S., Zhou, J., and Bragulat, V. (2019). Phase I\/II, open-label, 2-arm study to evaluate safety, tolerability, and clinical activity of GSK2857916 in combination with 2 standard-of-care (SoC) regimens in relapsed\/refractory multiple myeloma: (DREAMM 6). J. Clin. Oncol., 37.","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8053"},{"key":"ref_21","first-page":"3153","article-title":"Preclinical Evaluation of MEDI2228, a BCMA-Targeting Pyrrolobenzodiazepine-Linked Antibody Drug Conjugate for the Treatment of Multiple Myeloma","volume":"130","author":"Kinneer","year":"2017","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/j.clml.2019.09.257","article-title":"MEDI2228, a novel BCMA pyrrolobenzodiazepine antibody drug conjugate, overcomes drug resistance and synergizes with bortezomib and DNA damage response inhibitors in multiple myeloma","volume":"19","author":"Tai","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-020-0745-9","article-title":"A novel BCMA PBD-ADC with ATM\/ATR\/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma","volume":"34","author":"Xing","year":"2020","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2018-99-113921","article-title":"Preclinical and Nonclinical Characterization of HPN217: A Tri-Specific T Cell Activating Construct (TriTAC) Targeting B Cell Maturation Antigen (BCMA) for the Treatment of Multiple Myeloma","volume":"132","author":"Law","year":"2018","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lin, L., Cho, S.F., Xing, L., Wen, K., Li, Y., Yu, T., Hsieh, P.A., Chen, H., Kurtoglu, M., and Zhang, Y. (2020). Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia.","DOI":"10.1038\/s41375-020-0951-5"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1200\/JCO.2019.37.15_suppl.8012","article-title":"Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma","volume":"37","author":"Bensinger","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1158\/0008-5472.CAN-13-1365","article-title":"T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing","volume":"74","author":"Kudo","year":"2014","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Cho, S.F., Lin, L., Xing, L., Li, Y., Yu, T., Anderson, K.C., and Tai, Y.T. (2020). BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12061473"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Allahyari, H., Heidari, S., Ghamgosha, M., Saffarian, P., and Amani, J. (2017). Immunotoxin: A new tool for cancer therapy. Tumour Biol., 39.","DOI":"10.1177\/1010428317692226"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.2014-0358","article-title":"Advances in anticancer immunotoxin therapy","volume":"20","author":"Alewine","year":"2015","journal-title":"Oncologist"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1634\/theoncologist.2019-0370","article-title":"Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia","volume":"25","author":"Kreitman","year":"2020","journal-title":"Oncologist"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/leu.2017.315","article-title":"Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients","volume":"32","author":"Bera","year":"2018","journal-title":"Leukemia"},{"key":"ref_36","first-page":"503","article-title":"Recombinant immunotoxins in the treatment of cancer","volume":"248","author":"Pastan","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.leukres.2014.06.014","article-title":"An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies","volume":"38","author":"Bera","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_38","unstructured":"Bera, T.K., and Pastan, I. (2020). Anti-BCMA immunotoxins with improved efficacy. in preparation."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"E504","DOI":"10.1002\/ajh.24548","article-title":"Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma","volume":"91","author":"Jain","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9189","DOI":"10.18632\/oncotarget.13984","article-title":"Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes","volume":"8","author":"Kolyvas","year":"2017","journal-title":"Oncotarget"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1073\/pnas.1821733116","article-title":"Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models","volume":"116","author":"Shancer","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","article-title":"Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters","volume":"29","author":"Strohl","year":"2015","journal-title":"BioDrugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/jmr.300010204","article-title":"Analysis and use of the serum albumin binding domains of streptococcal protein G","volume":"1","author":"Nygren","year":"1988","journal-title":"J. Mol. Recognit."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"E3501","DOI":"10.1073\/pnas.1721780115","article-title":"Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity","volume":"115","author":"Wei","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","first-page":"19","article-title":"Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma","volume":"1","author":"Shancer","year":"2018","journal-title":"Antib. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"11782","DOI":"10.1073\/pnas.1209292109","article-title":"Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes","volume":"109","author":"Liu","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.1073\/pnas.1405153111","article-title":"Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes","volume":"111","author":"Mazor","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.ajpath.2018.04.016","article-title":"Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins","volume":"188","author":"Mazor","year":"2018","journal-title":"Am. J. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1517\/14712598.3.1.179","article-title":"DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia","volume":"3","author":"Frankel","year":"2003","journal-title":"Expert Opin. Biol. Ther."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/10\/1387\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:14:48Z","timestamp":1760177688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/10\/1387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["biom10101387"],"URL":"https:\/\/doi.org\/10.3390\/biom10101387","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]}}}